Business Segments and Geographic Information

12 Months Ended

Sep. 28, 2013

Segment Reporting [Abstract]

Business Segments and Geographic Information

15. Business Segments and Geographic Information

The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The Company’s chief operating decision maker is the chief executive officer, and the Company’s reportable segments have been identified based on the types of products manufactured and the end markets to which the product are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income (loss) adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset impairment charges, contingent consideration charges, restructuring and divestiture charges, and other one-time or unusual items, and related tax effects.

Identifiable assets for the four principal operating segments consist of inventories, intangible assets including goodwill, and property and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company presents all other identifiable assets as corporate assets. There were no intersegment revenues. Segment information for fiscal 2013, 2012 and 2011 is as follows:

	Years ended
	September 28, 2013			September 29, 2012			September 24, 2011
Total revenues:
Diagnostics	$	1,189,819		$	718,064		$	571,263
Breast Health		905,076			875,771			825,551
GYN Surgical		307,139			313,089			300,538
Skeletal Health		90,245			95,728			91,997
	$	2,492,279		$	2,002,652		$	1,789,349
Operating (loss) income:
Diagnostics	$	(1,149,132	)	$	(32,787	)	$	170,693
Breast Health		216,049			186,106			187,970
GYN Surgical		19,664			(51,892	)		3,623
Skeletal Health		7,137			12,290			12,159
	$	(906,282	)	$	113,717		$	374,445
Depreciation and amortization:
Diagnostics	$	369,818		$	197,274		$	165,065
Breast Health		40,098			42,924			45,165
GYN Surgical		105,233			103,781			92,587
Skeletal Health		861			1,772			1,919
	$	516,010		$	345,751		$	304,736
Capital expenditures:
Diagnostics	$	51,653		$	44,939		$	23,128
Breast Health		16,386			9,821			12,069
GYN Surgical		9,145			12,233			11,467
Skeletal Health		562			171			2,198
Corporate		12,384			11,609			6,801
	$	90,130		$	78,773		$	55,663
Identifiable assets:
Diagnostics	$	4,667,942		$	6,170,553		$	1,770,107
Breast Health		932,206			956,134			985,196
GYN Surgical		1,849,518			1,944,386			2,049,682
Skeletal Health		33,508			32,778			31,864
Corporate		1,517,649			1,373,257			1,171,931
	$	9,000,823		$	10,477,108		$	6,008,780

In fiscal 2013, the Company recorded a goodwill impairment charge of $1.1 billion related to its Molecular Diagnostics reporting unit, which is in its Diagnostics segment. In fiscal 2012, the Company recorded a goodwill impairment charge of $5.8 million related to its MammoSite reporting unit, which is in its Breast Health segment.

Products sold by the Company internationally are manufactured at domestic and international locations. Transfers between the Company and its subsidiaries are generally recorded at amounts similar to the prices paid by unaffiliated foreign dealers. All intercompany profit is eliminated in consolidation.

The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location, and internationally totaled $621.7 million, $511.2 million and $414.4 million in fiscal 2013, 2012 and 2011, respectively. The Company’s sales in Europe are predominantly derived from Germany, the United Kingdom and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East.

Revenues by geography as a percentage of total revenues are as follows:

	Years ended
	September 28, 2013			September 29, 2012			September 24, 2011
United States		75	%		74	%		77	%
Europe		13	%		12	%		14	%
Asia-Pacific		8	%		8	%		6	%
All others		4	%		6	%		3	%
		100	%		100	%		100	%

The Company’s property and equipment, net are geographically located as follows:

	September 28, 2013		September 29, 2012		September 24, 2011
United States	$	386,049	$	405,141	$	165,177
Costa Rica		29,258		30,452		34,107
Europe		61,472		59,927		29,591
All other countries		14,749		12,478		9,791
	$	491,528	$	507,998	$	238,666